At a glance
A secretagogue used to investigate ghrelin-receptor signaling.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source reports hormone-response experiments and broader body-composition discussions. A rise in GH or IGF-1 is a biomarker finding, not a complete assessment of benefit and risk.[1][5][3]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of GHRP-2.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 2 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 100 mcg (0.1 mg) | 3 units (0.03 mL) |
| Weeks 3–4 | 150 mcg (0.15 mg) | 4.5 units (0.045 mL) |
| Weeks 5–8 | 200 mcg (0.2 mg) | 6 units (0.06 mL) |
| Weeks 9–12 (optional) | 250–300 mcg (0.25–0.3 mg) | 7.5–9 units (0.075–0.09 mL) |
Frequency: Inject once daily subcutaneously, typically before sleep to coincide with natural GH pulsatility[4]. For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Advanced / Aggressive Approach (Multiple Daily Dosing)
| Phase | Per‑Injection Dose (mcg) | Frequency | Units (per injection) (mL) |
|---|---|---|---|
| Phase 1 (Weeks 1–2) | 100 mcg (0.1 mg) | 2× daily | 3 units (0.03 mL) |
| Phase 2 (Weeks 3–4) | 150 mcg (0.15 mg) | 2× daily | 4.5 units (0.045 mL) |
| Phase 3 (Weeks 5–8) | 200 mcg (0.2 mg) | 2–3× daily | 6 units (0.06 mL) |
Published human research tested once-daily subcutaneous GHRP-2 over five days and documented response attenuation[4]. Treat the multiple-daily table below as a research calculation model, not as a schedule established by that study. Note: Total daily doses in the 600–900 mcg range (split across injections) have been studied but may accelerate GH response attenuation[4]. A 5‑days‑on/2‑days‑off cycling pattern may help maintain receptor sensitivity[7]. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Stimulate pulsatile growth hormone release and elevate IGF‑1 levels over time[5].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 100–300 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; use within ~4 weeks after reconstitution[8].
Suggested daily titration approach.
- Start: 100 mcg daily; increase by ~50 mcg every 1–2 weeks as tolerated[3].
- Target: 200 mcg daily by Weeks 5–8; optional increase to 250–300 mcg in Weeks 9–12.
- Frequency: Once per day (subcutaneous); advanced protocols may use 2–3× daily.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with periodic breaks.
- Timing: Typically before sleep or on empty stomach; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[8].
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; stable for 1+ years frozen.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within ~4 weeks; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- Use bacteriostatic water (0.9% benzyl alcohol) for multi‑dose reconstitution[9].
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[10][11].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[11].
- For very lean individuals, use a 45° angle to avoid intramuscular injection[10].
- Inject slowly and steadily; do not aspirate for subcutaneous injections.
- Rotate sites systematically (abdomen at least 2 inches from navel, thighs, upper arms) to avoid lipohypertrophy[11].
- Dispose of used syringes immediately in a sharps container; never recap needles.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration (once‑daily schedule).
-
Peptide Vials (GHRP-2, 10 mg each):
- 8 weeks ≈ 1 vial (~9.1 mg used)
- 12 weeks ≈ 2 vials (~15.4 mg used)
- 16 weeks ≈ 3 vials (~22.4 mg used)
-
Insulin Syringes (U‑100, 30‑ or 50‑unit recommended for precision):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (1 vial): 3 mL → 1 × 10 mL bottle
- 12 weeks (2 vials): 6 mL → 1 × 10 mL bottle
- 16 weeks (3 vials): 9 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
- Sharps Container: 1‑quart container holds ~100 syringes; 2‑quart for 16‑week protocols.
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
PubMed — Growth hormone response to GHRP-2 (PMC3297037) — Pituitary and hypothalamic mechanisms of GH release stimulation (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 03
Research publication
Pihoker C. et al. (1995) — J Clin Endocrinol Metab — Diagnostic studies with IV and intranasal GHRP-2 in children of short stature (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Nijland EA. et al. (1998) — Eur J Endocrinol — Five‑day SC GHRP-2 treatment causes response attenuation in young men (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
- 09
Source document
Mountainside Medical — Bacteriostatic Water vs Sterile Water — Multi‑dose vial guidelines; 28‑day use recommendation (opens in a new tab)www.mountainside-medical.com
Back to overview ↑ - 10
Research publication
Usach I. et al. (2019) — Adv Ther (PMC6822791) — Subcutaneous injection of drugs: factors influencing pain and technique (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Public health resource
MedlinePlus — Subcutaneous (SQ) Injections — Site selection, angle guidance, and rotation best practices (opens in a new tab)medlineplus.gov
Back to overview ↑ - 13
Public health resource
NCBI Bookshelf — Best Practices for Injections — Asepsis, preparation, and administration standards (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
Research publication
Domest Anim Endocrinol — Effects of GHRP-2 on GH release and growth performance in swine (mechanism and receptor activation) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 16
Research publication
J Clin Endocrinol Metab — Effects of eight months treatment with graded doses of GHRP-2 in GH-deficient children (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 17
Research publication
Endocrine — GH/IGF-1 response to acute and chronic GHRP-2, GHRH 1-44, and their combination in older adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 18
Research publication
Am J Men’s Health — Growth hormone secretagogue treatment in hypogonadal men raises serum IGF-1 levels (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 19
Research publication
Sex Med Rev (PMC) — The safety and efficacy of growth hormone secretagogues: comprehensive review (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 22
- 23
Continue exploring
Related topics are not interchangeable compounds or formulations.